Latest Breaking News On - Lancet haematology - Page 1 : vimarsana.com

AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and...

Researchers identify safety of a potential new treatment to manage complications from sickle cell disease

AstraZeneca : Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH - Form 6-K -April 02, 2024 at 08:48 am EDT

a9026i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

AstraZeneca (AZN) announces Voydeya approved in the US

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

AstraZeneca's Rare Disease Pipeline Notches Another FDA Approval

The FDA approved AstraZeneca drug Voydeya as an add-on to standard therapies for paroxysmal nocturnal hemoglobinuria, a rare blood disorder. Alexion, now AstraZeneca’s rare disease subsidiary, added the small molecule to its pipeline via a 2019 acquisition.

Researchers help spearhead changes to global anemia guidelines

New research finds oral leukemia therapy to work as well as intravenous decitabine